Claims for Patent: 8,283,357

Summary for Patent: 8,283,357

Title:	Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
Abstract:	The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. ##STR00001##
Inventor(s):	Venkataramani; Chandrasekar (Redwood City, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	12/795,575
Patent Claims:	1. A compound selected from those of Formula (I) and pharmaceutically accepted salts thereof: ##STR00502## wherein Cy.sup.1 is cycloalkylidene or heterocycloalkylidene; R.sup.1 and R.sup.2 are independently selected from the group consisting of: (a) H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, and arylalkyl; and (b) R.sup.8--C(O)--X.sup.1--, R.sup.8--O--C(O)--X.sup.1-- and R.sup.8--S(O).sub.a--X.sup.1--, wherein X.sup.1 is selected from the group consisting of a bond, --NH--C.sub.1-6 alkylene, --O--C.sub.1-6 alkylene, C.sub.1-6 alkylene, C.sub.2-6 akenylene, C.sub.2-6 alkynylene, C.sub.3-6 cycloalkylene, arylene, and heterocyclylene; R.sup.8 is selected from the group consisting of H, hydroxy, amino, alkyl, alkoxy, N-alkylamino, N,N-dialkylamino, cycloalkyl, and heterocyclyl; and a is 0, 1 or 2; wherein each R.sup.1 and R.sup.2 is optionally substituted with one or more A where such an optional substitution is chemically feasible; R.sup.3 is independently selected from the group consisting of: (a) cyano, oxo, halo, nitro, hydroxy, amino, mercapto, alkyl, aryl, cycloalkyl, heterocyclyl, and heterocyclylalkyl; (b) R.sup.9--C(O)--X.sup.2--, R.sup.9--O--C(O)--X.sup.2-- and R.sup.9--S(O).sub.a--X.sup.2--, wherein X.sup.2 is selected from the group consisting of a bond, --NH--C.sub.1-6 alkylene, --O--C.sub.1-6 alkylene, C.sub.1-6 alkylene, C.sub.2-6 akenylene, C.sub.2-6 alkynylene, C.sub.3-6 cycloalkylene, arylene, and heterocyclylene; and a is 0, 1 or 2, wherein R.sup.1 is optionally substituted with one or more B where such an optional substitution is chemically feasible; or when m is 2, the two R.sup.1 groups can be substituted on the same carbon ring atom of Cy and together with the carbon ring atom of Cy for in a ring situated on Cy in a spiro configuration, wherein the spiro ring is cycloalkyl or heterocycloalkyl; two groups R.sup.3 are substituted on the same carbon ring atom of Cy.sup.1 and together with the carbon ring atom of Cy.sup.1 form a ring situated on Cy.sup.1 in a spiro configuration, wherein the spiro ring is cycloalkyl or heterocycloalkyl; m is an integer from 0 to the maximum number of substitutable positions on Cy.sup.1; R.sup.4 is selected from the group consisting of --H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, aralkyl, heteroaralkyl, alkylamino, alkylaminoalkyl, cycloalkylamino, heterocycloalkylamino, and arylamino, wherein R.sup.4 is optionally substituted with one or more selected from halo, oxo, hydroxyl, amino, alkylamino, carbamoyloxy, carbamoyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl where such an optional substitution is chemically feasible; R.sup.5 is independently selected from the group consisting of halo, hydroxy, nitro, cyano, haloalkyl, haloalkoxy, amino, carboxy, carbamoyl, sulphamoyl, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 alkyl).sub.2 amino, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 alkyl).sub.2 carbamoyl, C.sub.1-10 alkyl-S(O).sub.a wherein a is 0, 1 or 2, NH.sub.2--S(O).sub.2NH--, N--(C.sub.1-10 alkyl)sulphamoyl, N,N--(C.sub.1-10 alkyl).sub.2sulphamoyl, cycloalkyl, heterocyclyl and aryl; n is 0, 1, 2, 3 or 4; R.sup.6 is independently selected from the group consisting of --H, halo, haloalkyl, aryl and heteroaryl wherein the aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of amino, halo, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; o is 0, 1, 2, 3 or 4; R.sup.7 is NH.sub.2-- or OH--; A is independently selected from the group consisting of oxo, halo, amino, hydroxyl, cyano, carbamoyl, C.sub.1-10 alkyl, C.sub.1-10 alkoxy, C.sub.1-10 haloalkyl, C.sub.1-10 alkanoylamino, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 dialkyl)amino, C.sub.1-10 alkanoyl, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 dialkyl)carbamoyl, C.sub.3-10 cycloalkyl, (C.sub.3-10 cycloalkyl)C.sub.1-10 alkyl, C.sub.3-10 cycloalkoxy, C.sub.1-10 haloalkoxy, heterocycloalkyl, (heterocycloalkyl)C.sub.1-10 alkyl, aryl, (aryl)C.sub.1-10 alkyl, heteroaryl, (heteroaryl)C.sub.1-10 alkyl and R(R')(R'')silyl wherein R, R' and R'' are independently alkyl or aryl, or when R.sup.1 or R.sup.2 is a saturated or unsaturated cyclic group, two A groups can be substituted at adjacent positions of R.sup.1 or R.sup.2 and form a 5- or 6-membered, saturated or unsaturated cyclic moiety to make a fused ring with R.sup.1 or R.sup.2, wherein the cyclic moiety can contain one or more heteroatoms selected from N, O and S; and B is independently selected from the group consisting of halo, amino, carboxy, carbamoyl, C.sub.1-10 alkyl, C.sub.1-10 alkoxy, N--(C.sub.1-10 alkyl)amino, N,N--(C.sub.1-10 dialkyl)amino, N--(C.sub.1-10 alkyl)carbamoyl, N,N--(C.sub.1-10 dialkyl)carbamoyl, C.sub.1-10 haloalkyl, C.sub.3-10 cycloalkyl, C.sub.3-10 heterocycloalkyl, C.sub.3-10 aryl, heteroaryl, (C.sub.1-10 alkyl)C.sub.3-10 cycloalkyl and R(R')(R'')silyl wherein R, R' and R'' are independently alkyl or aryl. 2. The compound of claim 1, wherein Cy.sup.1 is C.sub.3-7 cycloalkylidene or heterocycloalkylidene having from 3 to 7 ring members. 3. The compound of claim 1, wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of --H, alkyl, and carboxy, wherein each R.sup.1 and R.sup.2 is optionally substituted by one or more A selected from the group consisting of halo, hydroxy, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, aralkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl. 4. The compound of claim 1, wherein R.sup.4 is selected from the group consisting of methyl, cyclopropyl, cyclopropylmethyl, trifluoroethyl, N,N-dimethylaminoethyl, pyrrolidinylethyl, benzyl, pyridinylmethyl, ethylpyridinylmethyl, acetylpiperazinylethyl, methylsulfonamidoethyl, methoxyethyl, methoxycarbonylaminoethyl, pyrazinylaminoethyl, chlorofluorobenzyl, trifluoromethylpyridinylmethyl, imidazolylethyl, imidazolylmethyl, methyldioxopiperidinylmethyl, dioxopyrrolidinylethyl, N,N-dimethylcarbamoylmethyl morpholinocarbonylethyl, hydroxymethylpropyl, fluorophenyl, and tetrahydropyranyl. 5. The compound of claim 1, wherein R.sup.6 and R.sup.7 are selected to make any of the following substitutions on the phenyl ring attached to the -phenyl-C(O)--NH-- linker: ##STR00503## wherein the wavy line is an attachment position to the -phenyl-C(O)--NH-- linker. 6. The compound of claim 1 selected from those of Formula (I-a) and pharmaceutically acceptable salts thereof: ##STR00504## wherein R.sup.3 is independently selected from the group consisting of halo, hydroxy, alkyl, and aryl; and m is 0, 1 or 2. 7. The compound of claim 6, wherein R.sup.1 and R.sup.2 optionally substituted with one or more A are independently selected from the group consisting of H, methyl, butyl, tetrahydrofuranylmethyl, alkylazetidinyl, alkylpiperidinyl, cyclopentyl, oxoimidazolidinylethyl, alkyloxopiperidinyl, trifluorophenylethyl, trifluoropyridinylethyl, alkylphenylcyclopropyl, hydroxy, trifluoromethylpentynyl, cyclopropylpropynyl, hydroxybutynyl, methylcyclopropoxycarbonyl, tert-butoxycarbonyl, trifluoromethylpropoxycarbonyl, benzoxycarbonyl, pyridinylmethoxycarbonyl, trifluoromethylpyridinylmethoxycarbonyl, cyclopropylpyridinylmethoxycarbonyl, phenylethoxycarbonyl, quinolinylmethoxycarbonyl, morpholinoethoxycarbonyl, N,N-dimethylcarbamoyl, morpholinylcarbonyl, N-t-butylcarbamoyl, benzenoyl, nicotinoyl, quinolinoyl, cyclopropanoyl, propanoyl, isobutanoyl, methoxypropanoyl, dimethylaminopropanoyl, trifluoroethyl, trifluoropropyl, trifluoromethylcyclopropyl, methylsulfonyl, trifluoroethylsulfonyl, cyclopropylsulfonyl, phenylsulfonyl, pyridinylsulfonyl, trifluoromethylpyridinylsulfonyl, quinolinylsulfonyl, sulfalmoyl, dimethylsulfamoyl, morpholinylsulfonyl, aminothiadiazolylethyl, tetrahydropyranylethyl, thiophenylethyl, ##STR00505## 8. The compound of claim 6, wherein R.sup.1 is --H; and R.sup.2 is R.sup.10--O--C(O)--X.sup.3--, wherein R.sup.2 is optionally substituted with one or more A. 9. The compound of claim 6, wherein R.sup.4 is selected from methyl, cyclopropyl, cyclopropylmethyl, trifluoroethyl, N,N-dimethylaminoethyl, pyrrolidin-1-ylethyl, benzyl, pyridin-2-ylmethyl, (1-ethylpyridin-4-yl)methyl, 4-acetylpiperazin-1-ylethyl, methylsulfonamidoethyl, methoxyethyl, methoxycarbonylaminoethyl, pyrazin-2-ylaminoethyl, 2-chloro-4-fluoro-benzyl, (5-(trifluoromethyl)pyridin-2-yl)methyl, (1H-imidazol-1-yl)ethyl, (1H-imidazol-2-yl)methyl, (1-methyl-2,6-dioxopiperidin-4-yl)methyl, 2,5-dioxopyrrolidin-1-ylethyl, N,N-dimethylcarbamoyl, morpholinocarbonylmethyl, 2-hydroxy-2-methylpropyl, 4-fluorophenyl, and tetrahydro-2H-pyran-4-yl. 10. The compound of claim 6, wherein R.sup.5 is selected from halo, hydroxy, alkyl and haloalkyl. 11. The compound of claim 6, wherein R.sup.6 is selected from fluoro, trifluoromethyl, phenyl, fluorophenyl, thiophenyl, chlorothiophenyl and methylthiophenyl. 12. The compound of claim 6, which is selected from the group consisting of ##STR00506## ##STR00507## 13. The compound of claim 1 selected from those of Formula (I-b) and pharmaceutically acceptable salts thereof: ##STR00508## wherein R.sup.3 is independently selected from the group consisting of halo, hydroxy, alkyl, and aryl; and p is 2, 3, 4 or 5. 14. The compound of claim 13, wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of H, methyl, tert-butyl, (6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, (2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl, tetrahydrofuran-2-ylmethyl, 2-alkylisoindolin-5-ylmethyl, 1-alkylazetidin-3-yl, 1-alkylpiperidin-3-yl, 1-alkylpyrrolidin-2-yl, cyclopentyl, 2-oxoimidazolidin-1-ylethyl, isochroman-4-yl, 2,2-dimethylchroman-4-yl, 1-alkyl-2-oxopiperidin-3-yl, 2,2,2-trifluoro-1-phenylethyl, 2,2,2-trifluoro-1-(pyridin-2-yl)ethyl, 1-alkylphenylcyclopropyl, 5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)pent-2-ynyl, 3-cyclopropylprop-2-ynyl, 4-hydroxy-4-methylpent-2-ynyl, 1-methylcyclopropoxycarbonyl, tert-butoxycarbonyl, 1,1,1-trifluoro-2-methylprop-2-oxycarbonyl, benzoxycarbonyl, pyridin-3-ylmethoxycarbonyl, 5-trifluoromethylpyridin-3-ylmethoxycarbonyl, 5-cyclopropylpyridin-3-ylmethoxycarbonyl, 1-phenylethoxycarbonyl, quinolin-3-ylmethoxycarbonyl, 2-morpholinoethoxycarbonyl, N,N-dimethylcarbamoyl, morpholin-4-ylcarbonyl, N-t-butylcarbamoyl, benzenoyl, nicotinoyl, quinolinoyl, cyclopropanoyl, propanoyl, isobutanoyl, methoxypropanoyl, N,N-dimethylaminopropanoyl, 2,2,2-trifluoroethyl, 1,1,1-trifluoroprop-2-yl, 1-trifluoromethylcyclopropyl, methylsulfonyl, 2,2,2-trifluoroethylsulfonyl, cyclopropylsulfonyl, phenylsulfonyl, pyridin-3-ylsulfonyl, 5-trifluoromethylpyridin-3-ylsulfonyl, quinoline-3-sulfonyl, sulfalmoyl, dimethylsulfamoyl, morpholin-4-ylsulfonyl, 2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl, 1-(carboxymethyl)-2-oxo-piperidin-3-yl, 2-(5-amino-1,3,4-thiadiazol-2-yl)ethyl, 2-(tetrahydro-2H-pyran-2-yl)ethyl, and 2-(thiophen-2-yl)ethyl, wherein each of R.sup.1 and R.sup.2 is optionally substituted by one or more A. 15. The compound of claim 13, wherein R.sup.1 is --H; and R.sup.2 is R.sup.10--O--C(O)--X.sup.3-- wherein R.sup.2 is optionally substituted with one or more A. 16. The compound of claim 13, wherein R.sup.4 is selected from methyl, cyclopropyl, cyclopropylmethyl, trifluoroethyl, N,N-dimethylaminoethyl, pyrrolidin-1-ylethyl, benzyl, pyridin-2-ylmethyl, (1-ethylpyridin-4-yl)methyl, 4-acetylpiperazin-1-ylethyl, methylsulfonamidoethyl, methoxyethyl, methoxycarbonylaminoethyl, pyrazin-2-ylaminoethyl, 2-chloro-4-fluoro-benzyl, (5-(trifluoromethyl)pyridin-2-yl)methyl, (1H-imidazol-1-yl)ethyl, (1H-imidazol-2-yl)methyl, (1-methyl-2,6-dioxopiperidin-4-yl)methyl, 2,5-dioxopyrrolidin-1-ylethyl, N,N-dimethylcarbamoyl, morpholinocarbonylmethyl, 2-hydroxy-2-methylpropyl, 4-fluorophenyl, and tetrahydro-2H-pyran-4-yl. 17. The compound of claim 13, wherein R.sup.5 is selected from halo, hydroxy, alkyl and haloalkyl. 18. The compound of claim 13, wherein R.sup.6 is selected from fluoro, trifluoromethyl, phenyl, fluorophenyl, thiophenyl, chlorothiophenyl and methylthiophenyl. 19. The compound of claim 13, which is selected from the group consisting of ##STR00509## 20. The compound of claim 1 selected from those of Formula (I-c) and pharmaceutically acceptable salts thereof: ##STR00510## wherein p is 2, 3, 4 or 5, and Q is independently selected from the group consisting of --CH.sub.2--, --NH--, --O-- and --S--, wherein at least one Q is a non-carbon ring atom. R.sup.3 is independently selected from the group consisting of halo, hydroxy, alkyl, and aryl; R.sup.5 is independently selected from the group consisting of halo, hydroxy, haloalkyl, haloalkoxy, amino, carboxy, C.sub.1-10 alkyl, C.sub.1-10 alkoxy, C.sub.1-10 alkanoyl, N--(C.sub.1-10 alkyl)amino, and N,N--(C.sub.1-10 alkyl).sub.2 amino; and p is 1, 2, 3, 4 or 5. 21. The compound of claim 20, wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of H, methyl, tert-butyl, (6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, (2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl, tetrahydrofuran-2-ylmethyl, 2-alkylisoindolin-5-ylmethyl, 1-alkylazetidin-3-yl, 1-alkylpiperidin-3-yl, 1-alkylpyrrolidin-2-yl, cyclopentyl, 2-oxoimidazolidin-1-ylethyl, isochroman-4-yl, 2,2-dimethylchroman-4-yl, 1-alkyl-2-oxopiperidin-3-yl, 2,2,2-trifluoro-1-phenylethyl, 2,2,2-trifluoro-1-(pyridin-2-yl)ethyl, 1-alkylphenylcyclopropyl, 5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)pent-2-ynyl, 3-cyclopropylprop-2-ynyl, 4-hydroxy-4-methylpent-2-ynyl, 1-methylcyclopropoxycarbonyl, tert-butoxycarbonyl, 1,1,1-trifluoro-2-methylprop-2-oxycarbonyl, benzoxycarbonyl, pyridin-3-ylmethoxycarbonyl, 5-trifluoromethylpyridin-3-ylmethoxycarbonyl, 5-cyclopropylpyridin-3-ylmethoxycarbonyl, 1-phenylethoxycarbonyl, quinolin-3-ylmethoxycarbonyl, 2-morpholinoethoxycarbonyl, N,N-dimethylcarbamoyl, morpholin-4-ylcarbonyl, N-t-butylcarbamoyl, benzenoyl, nicotinoyl, quinolinoyl, cyclopropanoyl, propanoyl, isobutanoyl, methoxypropanoyl, N,N-dimethylaminopropanoyl, 2,2,2-trifluoroethyl, 1,1,1-trifluoroprop-2-yl, 1-trifluoromethylcyclopropyl, methylsulfonyl, 2,2,2-trifluoroethylsulfonyl, cyclopropylsulfonyl, phenylsulfonyl, pyridin-3-ylsulfonyl, 5-trifluoromethylpyridin-3-ylsulfonyl, quinoline-3-sulfonyl, sulfalmoyl, dimethylsulfamoyl, morpholin-4-ylsulfonyl, 2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl, 1-(carboxymethyl)-2-oxo-piperidin-3-yl, 2-(5-amino-1,3,4-thiadiazol-2-yl)ethyl, 2-(tetrahydro-2H-pyran-2-yl)ethyl, and 2-(thiophen-2-yl)ethyl, wherein each of R.sup.1 and R.sup.2 is optionally substituted by one or more A. 22. The compound of claim 20, wherein R.sup.1 is --H; and R.sup.2 is R.sup.10--O--C(O)--X.sup.3--, wherein R.sup.2 is optionally substituted with one or more A. 23. The compound of claim 20, wherein R.sup.4 is selected from methyl, cyclopropyl, cyclopropylmethyl, trifluoroethyl, N,N-dimethylaminoethyl, pyrrolidin-1-ylethyl, benzyl, pyridin-2-ylmethyl, (1-ethylpyridin-4-yl)methyl, 4-acetylpiperazin-1-ylethyl, methylsulfonamidoethyl, methoxyethyl, methoxycarbonylaminoethyl, pyrazin-2-ylaminoethyl, 2-chloro-4-fluoro-benzyl, (5-(trifluoromethyl)pyridin-2-yl)methyl, (1H-imidazol-1-yl)ethyl, (1H-imidazol-2-yl)ethyl, (1-methyl-2,6-dioxopiperidin-4-yl)methyl, 2,5-dioxopyrrolidin-1-ylethyl, N,N-dimethylcarbamoyl, morpholinocarbonylmethyl, 2-hydroxy-2-methylpropyl, 4-fluorophenyl, and tetrahydro-2H-pyran-4-yl. 24. The compound of claim 20, wherein R.sup.5 is selected from halo, hydroxy, alkyl and haloalkyl. 25. The compound of claim 20, wherein R.sup.6 is selected from fluoro, trifluoromethyl, phenyl, fluorophenyl, thiophenyl, chlorothiophenyl and methylthiophenyl. 26. The compound of claim 20, which is selected from the group consisting of ##STR00511## 27. A pharmaceutical composition comprising an effective amount of one or more compounds according to claim 1 and a pharmaceutically-acceptable carrier. 28. The pharmaceutical composition according to claim 27, further comprising one or more anti-cancer agents. 29. The pharmaceutical composition according to claim 28, wherein the one or more anti-cancer agents are selected from the group consisting of cyclophosphamide, dacarbazine, cisplatin, methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, vinblastine, paclitaxel, doxorubicin, bleomycin, mitomycin, prednisone, tamoxifen, flutamide, asparaginase, rituximab, trastuzumab, imatinib, retinoic acid, colony-stimulating factor, amifostine, lenalidomide, HDAC inhibitor, CDK inhibitor, camptothecin and topotecan. 30. A method of inhibiting or treating a disease arising from abnormal cell proliferation and/or differentiation in an animal, comprising administering to said animal a therapeutically effective amount of one or more compounds according to claim 1 or 28. 31. The method according to claim 30, wherein the animal is human. 32. The method according to claim 30, wherein the disease is mediated by a histone deacetylase. 33. The method according to claim 30, wherein the disease is selected from the group consisting of a cell proliferative disease, autosomal dominant disorder, genetic related metabolic disorder, fibrosis, autoimmune disease, diabetes, neurological disease, and Alzheimer's disease. 34. The method according to claim 30, wherein the disease is cancer selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, skin cancer and thyroid cancer. 35. The method according to claim 30, wherein the disease is pulmonary fibrosis or renal fibrosis.

Details for Patent 8,283,357

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2029-06-08
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2029-06-08
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2029-06-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2029-06-08